New eye injection for macular degeneration passes early safety check
NCT ID NCT05904691
First seen May 03, 2026 · Last updated May 20, 2026 · Updated 4 times
Summary
This early-stage trial tests the safety of an experimental drug called OCU-10-C-110 for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. The study involves 24 participants who receive one or more injections into the eye. Researchers monitor for side effects to see if the treatment is safe enough for further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Raj K. Maturi, M.D., P.C.
Carmel, Indiana, 46290, United States
-
Retina Research Institute of Texas
Abilene, Texas, 79606, United States
-
Strategic Clinical Research Group LLC
Willow Park, Texas, 76087, United States
Conditions
Explore the condition pages connected to this study.